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Abstract
Introduction Dilmapimod is a potent p38 mitogen-acti-
vated protein kinase (MAPK) inhibitor and was investi-
gated in a study (NCT00996840) for its anti-inflammatory
effect in non-head injury trauma patients at risk for
developing acute respiratory distress syndrome (ARDS).
The purpose of this paper is to present the details of the
development of a population pharmacokinetic (PK) model,
an empirical population placebo response model, and the
exploration of a PK/pharmacodynamic (PD) model of
dilmapimod.
Methods A population PK model was developed to char-
acterise the PK profile of dilmapimod in this patient pop-
ulation; the potential effect of available covariates on the
PK of dilmapimod was evaluated. An empirical population
placebo response model was conducted, and a population
PK/PD model was explored to evaluate the relationship
between dilmapimod concentration and C-reactive protein
(CRP) (a systemic biomarker of p38 inhibition). All anal-
yses were performed using NONMEM software.
Results Following intravenous dosing, dilmapimod was
quickly distributed to peripheral compartments and then
slowly eliminated. The plasma concentration of dilmapi-
mod was adequately described by a three-compartment
model. It increased approximately proportionally to the
increase in dose. The population clearance (CL) parameter
value was 35.87 L/h, and the steady-state volume of dis-
tribution (Vss) [sum of the volume of distribution of the
central compartment (Vc) and of the peripheral compart-
ments V2 and V3] was 160 L. The effect of body mass
index (BMI) on CL and inter-compartment clearance (Q2)
was found statistically significant, with an increase in BMI
of 1 kg/m2 resulting in a 1.79 L/h and 0.52 L/h increase in
CL and Q2, respectively. The CRP profile post injury was
adequately described by an indirect response model, with a
sharp increase in the CRP levels following injury, followed
by them slowly diminishing. Data exploration indicated
potential drug effects of dilmapimod on inhibiting the
production of CRP levels; however, the current small
dataset did not show a statistically significant improvement
in the PK/PD modelling.
Conclusion The population PK modelling adequately
evaluated the dilmapimod plasma concentration–time
profiles in severe trauma subjects at risk for ARDS, and
BMI was found to be a significant covariate in the PK
model. An indirect response model was adequate to
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Key Points
Dilmapimod plasma concentration–time profiles in
severe trauma subjects at risk for acute respiratory
distress syndrome were adequately described by a
three-compartment model. Following intravenous
dosing, dilmapimod was quickly distributed to
peripheral compartments and then slowly eliminated
in a multi-exponential manner. The plasma
concentration of dilmapimod increased
approximately proportionally to the increase in dose.
Body mass index was a significant covariate in the
pharmacokinetic model.
The C-reactive protein (CRP) profile post injury was
adequately described by an indirect response model,
with a sharp increase in the CRP levels following
injury, followed by them slowly diminishing. There
was a trend in dilmapimod inhibiting the production
of CRP; the current small dataset did not show a
statistically significant improvement in the
pharmacokinetic/pharmacodynamic modelling.
1 Introduction
Acute respiratory distress syndrome (ARDS) is a life-
threatening complex condition associated with severe
hypoxia and respiratory failure. Despite improved under-
standing of the pathogenesis of the disease, there is no
effective pharmacological treatment for ARDS [1, 2].
Severe trauma has been recognised as a potential cause
of ARDS due to indirect lung injury [3]. Tissue injury
following trauma is mediated by multiple immunological
processes involving neutrophils, macrophages, and den-
dritic cells, leading to elevated levels of circulating pro-
inflammatory cytokines such as interleukin 6 (IL-6),
tumour necrosis factor alpha (TNF-a), and IL-8, both in the
lungs and in systemic circulation [1]. Therefore, attenua-
tion of pro-inflammatory cytokine signalling may be ben-
eficial in both treatment and prevention of ARDS.
The p38 mitogen-activated protein kinase (MAPK) is a
serine-threonine protein kinase that phosphorylates intra-
cellular signal transduction molecules involved in the
regulation of inflammatory cytokine biosynthesis [4–7]. It
is believed that activation of the p38 MAPK pathway is
involved in the mechanism of ARDS [8, 9]; therefore,
inhibition of the p38 MAPK signalling pathway at the early
stage of ARDS may lead to decreased expression of pro-
inflammatory cytokines known to be involved in the
pathophysiology of ARDS.
Dilmapimod is a potent inhibitor of the p38 MAPK
pathway. Multiple studies have evaluated and shown its
pharmacological effect in inhibiting production of cytoki-
nes in different disease populations following oral admin-
istration [4–7]. However, no systemic pharmacokinetic
(PK) data were reported in those studies.
The study we report on in this paper was conducted to
investigate the hypothesis of p38 inhibition in the early
stage of ARDS, and to evaluate the safety, tolerability, PK
and pharmacodynamics (PD) of dilmapimod following
intravenous administration in non-head injury trauma
patients at risk for developing ARDS. The study objectives,
endpoints, inclusion and exclusion criteria, as well as the
primary results have been described elsewhere [10].
The aim of this paper is to present the details of the
development of a population PK model, an empirical pla-
cebo response model, and the exploration of a population
PK/PD model of dilmapimod. Specifically, the following
analyses were conducted: (1) a population PK model was
developed to characterise the PK profile of dilmapimod in
this patient population; (2) the potential effect of available
covariates on the PK of dilmapimod was evaluated; and (3)
a population PK/PD model was conducted to evaluate the
relationship between dilmapimod concentration and C-re-
active protein (CRP), a systemic biomarker of p38 inhibi-




A phase IIa, randomised, double-blind, placebo-controlled,
parallel-group study was conducted at six sites in the USA
to evaluate the safety, tolerability, and systemic PK and PD
profiles of dilmapimod compared with placebo in patients
with major trauma (exclusive of severe head injury) and at
risk for developing ARDS (clinicaltrial.gov
NCT00996840). Details of the study’s design are provided
in Christie et al. [10]. Briefly, eligible subjects were ran-
domised into the trial within the first 24–26 h after known
trauma had occurred. Four cohorts were recruited and
dosed for 3 consecutive days via an intravenous infusion.
Cohort 1 patients were randomised 3:1 to receive 3 days of
dilmapimod (3 mg intravenously) infused over 4 h or
placebo; cohort 2 patients were randomised 2:1 to receive
3 days of dilmapimod (7.5 mg intravenously) infused over
24 h or placebo; cohort 3 patients were randomised 3:1 to
receive 3 days of dilmapimod (7.5 mg intravenously)
infused over 4 h or placebo; and cohort four patients were
randomised 3:1 to receive 3 days of dilmapimod (10 mg
intravenously) infused over 24 h or placebo. A follow-up
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visit was conducted on day 7, i.e. 4 days after intravenous
dosing had finished, or at discharge from the hospital if
earlier than day 7 (but no earlier than 12 h after dosing had
been completed).
Blood samples for PK analysis were collected at the
following times:
• For cohorts 1 and 3 (4 h infusion): on day 1, pre-dose
(before the first dose), then 4, 4.25, 5, 8, and 12 h after
the first dose; pre-dose on day 2 (before the second
dose) and day 3 (before the third dose); then 24 h after
the third dose.
• For cohorts 2 and 4 (24 h infusion): pre-dose on day 1
(before the first dose) and day 2 (before the second
dose); on day 3, pre-dose (before the third dose), then at
24 h (immediately before the infusion stopped), 24 h
10 min (10 min after the third dose), 24 h 45 min
(45 min after the third dose), 27 h (3 h after the third
dose), 34 h (10 h after the third dose), 40 h (16 h after
the third dose), and 48 h (24 h after the third dose).
Blood samples for the PD analysis for all four cohorts
were collected at the following times:
• Day 1: pre-dose and 6, 12, and 18 h after the first dose.
• Day 2: pre-dose.
• Day 3: pre-dose and 24 and 48 h after the third dose.
2.2 Analytical Method for PK Analysis
Human plasma samples were analysed for dilmapimod
(SB-681323) using a validated analytical method based on
protein precipitation, followed by high-performance liquid
chromatography–tandem mass spectrometry (HPLC–MS/
MS) analysis. The lower limit of quantification for
dilmapimod (SB-681323) was 0.1 ng/mL using a 50 lL
aliquot of human plasma and the higher limit of quantifi-
cation was 100 ng/mL.
Quality control samples (QC), prepared at three differ-
ent analyte concentrations and stored with study samples,
were included with each batch of samples along with
separately prepared calibration standards. For the analysis
to be acceptable, no more than one-third of the total QC
results and no more than one-half of the results from each
concentration level were to deviate from the nominal
concentration by more than 15%. The applicable analytical
runs met all predefined run acceptance criteria.
2.3 Analytical Method for the PD Analysis
Human serum CRP levels were quantified by an immuno-
turbidimetric assay (CRP Latex, Beckman Coulter, Pasa-
dena, California, USA), in which CRP reacts specifically
with anti-human CRP antibodies coated on latex particles
to yield insoluble aggregates. The absorbance of these
aggregates is proportional to the CRP concentration in the




A total of 471 dilmapimod concentration records from 57
subjects were available for inclusion in the PK analysis
dataset. Two outlier subjects (one from each of the 24-h
infusion groups; a total of 14 samples) with a concentration
range over the sampling interval over ten times greater than
the range observed in the majority of the subjects were
excluded from the model. Inclusion of these subjects
resulted in failure of minimisation. In addition, all post-
dose concentrations (seven samples) on day 3 and onward
from a subject in the 24-h 10-mg intravenous infusion
group were excluded because of missing infusion volume.
Furthermore, 19 samples at planned pre-dose time points
were excluded because their value was consistent with
being drawn after the start of infusion (sudden jump in
concentration at pre-dose following a decline in concen-
trations at the previous time points). In total, 40 concen-
tration records (8.5%) were excluded. Ten (2.1%) of the
concentrations were not quantifiable (NQ). All NQ values
were set to missing.
2.4.2 CRP Dataset
To assemble the PK/PD analysis dataset for CRP, the final
PK model was used to predict dilmapimod concentrations
at the times where the CRP biomarker was measured for
each patient in the dataset. The predicted concentrations
were merged into the CRP biomarker dataset and used in
the PK/PD analysis. The patients excluded from the PK/PD
analysis were the patients who had only dosing records in
the PK dataset, the patients excluded from the PK analysis
dataset because they had outlier profiles, and one additional
patient who had missing CRP measurements. Due to the
fact that no measurement of CRP was available for the time
of injury, the baseline CRP concentration at the time of
injury was assumed to be the CRP level for healthy indi-
viduals (1.35 mg/L, with added 10% variability to incor-
porate the uncertainty) [6, 11–15] (see Sect. 2.5.2.1 for
more details). The final PK/PD analysis dataset comprised
a total of 651 dilmapimod and CRP records (478 from
subjects on active treatment and 173 from subjects on
placebo) from 73 subjects (53 subjects on active treatment
and 20 placebo subjects).
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2.5 Methodology
The first-order conditional estimation method with inter-
action (FOCEI) was used for all PK and PK/PD analyses.
The analyses were conducted with NONMEM (version
7.1.2.) (ICON Development Solutions; Ellicott City, MD,
USA).
2.5.1 Population PK Modelling
Population PK modelling for dilmapimod was developed
using non-linear mixed-effects analyses. With yij indicating
the plasma concentration of the ith subject measured at
time tj, the nonlinear mixed effect model was described as:
yij ¼ f hi;Di; tj
  exp eij
  ð1Þ
where f represents the structural PK model, hi indicates the
PK parameters in the model for subject i, Di is the dose
administered for subject i, tj is the time of the plasma
concentration measurement, and eij is the residual error of
the measurement, and is assumed to follow normal distri-
bution with a mean of 0 and variance of r2.
Exploratory analysis of dilmapimod plasma concentra-
tion data in healthy subjects indicated that the best struc-
tural model to describe the dilmapimod PK was a three-
compartment model with first order elimination. The model
structure is shown in Fig. 1 (left panel). This model was
used for modelling the PK profile of dilmapimod in an
acute lung injury population. A two-compartment model
was also tested, but a three-compartment model described
the data better.
For a three-compartment model, hi = (CLi, Vci, V2i,
V3i, Q1i, Q2i), where CL is the population clearance, Vc,
V2, and V3 are the volumes of distribution for the central
compartment and the peripheral compartments, and Q1 and
Q2 are inter-compartment clearance values. All PK
parameters were described by population mean (hpop,k)
(k = 1, 2, …, 6) and a shift of the parameters for the ith
subject (ETAik) representing the inter-individual variabil-
ity, as shown below:
hik ¼ exp hpop;k þ ETAik
  ð2Þ
ETAik was assumed to follow normal distribution with a
mean of 0 and a variance–covariance matrix of Xk.
2.5.2 Population PK/PD Modelling
2.5.2.1 Base CRP Model An indirect response model,
shown in Fig. 1 (right panel) and Eq. (3), was applied to
describe the systemic CRP levels, where A(t) indicates the
amount of CRP in the system, Kin(t) and Kout(t) represent




¼ KinðtÞ  KoutðtÞ  AðtÞ ð3Þ
Based on the current understanding of the mechanism of
p38 pathways and the hypothesis for p38 inhibitors, it was
assumed that following injury (e.g. trauma), the p38
pathway was activated and therefore led to the
production of various cytokines and CRP. Although it is
not well known how CRP levels change over time after
injury, some literature data have indicated that the CRP
level quickly increases after injury in a few hours, reaches
peak and then gradually decreases [6, 12–15]. The
following mathematical function for Kin(t) was used to
model the change in CRP levels over time following the
placebo treatment:
Kin tð Þ ¼ Kin0  exp Kdecline  tð Þ ð4Þ
Fig. 1 Pharmacokinetic/pharmacodynamic (PK/PD) model for
dilmapimod and C-reactive protein (CRP). Dilmapimod PK were
described by a three-compartment model with first-order elimination
rates. The relationship between dilmapimod and CRP levels was
described using an indirect model with inhibition of CRP input. CL
clearance, Cp model-predicted dilmapimod concentration, IV intra-
venous, Kin zero-order production rate constant, Kout first-order
elimination rate constant, Q1 and Q2 inter-compartmental clearance,
Vc volume of distribution of the central compartment, V2 and V3
volume of distribution of the peripheral compartments
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where Kin0 was the CRP production rate immediately
following injury and exp(-Kdecline*t) was used to describe
the potential decline in production rate over time in order
to correspond to the hypothesis on the general profile of
CRP levels after injury without investigational drug.
It is noted that in order to solve the above differential
equation, A(0) is required. For this case, as there was no
measurement of CRP at time 0 (time of injury), A(0) was set
at the level of the corresponding CRP for healthy subjects.
For this work, A(0) = 1.35 mg/L (with added 10% vari-
ability to incorporate the uncertainty) for CRP [11].
2.5.2.2 Drug-Effect Models A brief synopsis of the
numerous drug-effect models explored is presented in
Table 1. Under the assumption that inhibition of p38
pathways by the p38 inhibitor, dilmapimod, would reduce
CRP production, the effect of dilmapimod on CRP was
assessed using inhibitory models, where the production rate
of CRP was affected by the level of dilmapimod concen-
tration (Cp) or by dilmapimod exposure [area under the
concentration–time curve (AUC)] in the plasma (Table 1).
In addition, indirect response models reflecting stimulation
of Kdecline or stimulation of the dissipation or response
(Kout) were also explored (Table 1).
The parameters in the models are as follows: h = (Kin0,
Kdecline, Kout, Imax, IC50, EFF, and c), where Imax represents
the maximum fractional (0–1) extent of inhibition, IC50 is
the concentration or AUC of dilmapimod that causes 50%
of the maximum effect (Imax), and c is the Hill coefficient.
Inter-individual variability is introduced by allowing all the
parameters to be varied for each individual subject by
hk = hk0*exp(gki), where hk0 indicates the typical value of
the kth parameter in the list, and gki * N(0,Xk) represents
the inter-subject variability on the kth parameter (k = 1, 2,
3, 4, 5, 6).
Additive and proportional error models were considered
to explore the residual variability on the CRPmeasurements.
2.6 Covariate Selection
Covariate analysis was performed to explore measurable
sources of variability in the models. Covariate effects were
considered for all the model parameters in the PK models
as well as parameters in the PK/PD models.
Demographics (age, gender, race, body weight, height),
clinical or medical status at entry, disease severity [defined
by Injury Severity Score (ISS)], creatinine clearance, and
liver function parameters (ALT, AST, total bilirubin and
albumin) were considered.




, where TVPKik is the typical value of kth PK
parameter for individual i, COVi is the value of the ith
subject covariate, REF is a value approximately the median
of the covariate in the population, and h indicates the
change in typical parameter value as the covariate changes.
For categorical covariates, TVPKik ¼ exp hpop;k
 
for
CATi = 0 and TVPKik ¼ exp hpop;k þ h
 
for CATi = 1,
where CATi represents the categorical covariate variable
for subject i.
Table 1 Indirect response
models used to investigate the
effect of dilmapimod on CRP
Inhibitory effect models on Kin:
dAðtÞ
dt
¼ KinðtÞ  ð1 EFFÞ  KoutðtÞ  AðtÞ
Kin ¼ Kin0  expðKdecline  tÞ
Inhibitory Emax EFF ¼ Imax XrIC50rþXr ; where X = Cp or AUC
Linear inhibitory effect of treatment vs. placebo EFF ¼ 0; if placebo
EFF ¼ EFF; if active treatment
Stimulatory effect on Kdecline:
dAðtÞ
dt
¼ KinðtÞ  KoutðtÞ  AðtÞ
Kin ¼ Kin0  exp½Kdecline  ð1þ EFFÞ  t
Stimulatory Emax EFF ¼ Imax Xr
IC50rþXr ; where X = AUC
Linear inhibitory effect of treatment vs. placebo EFF ¼ 0; if placebo
EFF ¼ EFF; if active treatment
Stimulatory effect on Kout:
dAðtÞ
dt
¼ KinðtÞ  KoutðtÞ  ð1þ EFFÞ  AðtÞ
Kin ¼ Kin0  exp½Kdecline  t
Inhibitory Emax EFF ¼ Imax Xr
IC50rþXr ; where X = Cp or AUC
Linear inhibitory effect of treatment vs. placebo EFF ¼ 0; if placebo
EFF ¼ EFF; if active treatment
AUC Area under the concentration–time curve, Cp model-predicted dilmapimod concentration, CRP C-reactive protein,
Emax maximum effect, EFF effect of dilmapimod, Kdecline decline in production rate of CRP, Kin production rate constant
of CRP, Kout elimination rate constant of CRP
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Potential covariate–parameter relationships were
explored graphically using the post hoc random effect
values for PK parameters (ETA in NONMEM modelling
language) versus each covariate and with simple and
multiple regression models using the generalised additive
model function (GAM) in Xpose4 (xpose.gam). The
selected covariates from these initial analyses were then
added to the base model one by one using the forward
addition technique, and then removed one at a time using
the backward elimination technique.
This forward building technique was continued until all
the potential influential covariates were included in the
model. The decrease in the objective function (D) was set to
[3.84 for a single covariate (p B 0.05) to be included in
the model. If removal of a covariate resulted in an increase
in the objective function (D) less than 6.63 (p B 0.01), the
covariate under examination was removed from the model.
The backward elimination technique continued until all the
covariates in the model passed all the criteria.
2.7 Model Diagnostics and Evaluations
Uncertainty in parameter estimates was assessed by stan-
dard error estimates (returned by NONMEM from the
$COVARIANCE step). Model selection was based on
successful minimisation, the objective function value,
parameter estimate plausibility, diagnostic plots, shrinkage
values, and acceptable relative standard error (RSE). The
adequacy of the final model was evaluated using the
standard goodness-of-fit method, including plots of popu-
lation and individual prediction versus observed data,
conditional weighted residual versus time, and the visual
predictive check method, which was based on 2000 repli-
cates of the original dataset. Model-simulated concentra-
tion–time data and associated median and 95% prediction
interval were compared with the observed data for each
dilmapimod treatment group (visual predictive check). The
vpc command of PsN (version 3.2.4) and xpose.VPC from
the XPOSE4 package [12] in R (R Core team 2012) were
Table 2 Parameter estimates of
fixed and random effects from
the final pharmacokinetic model
Parameter (unit) Typical value %RSEa Standard error 95% CIb or %CVc
CL (L/h) = exp(hpop,1) 35.9
hpop, 1 3.58 2.25 0.0806 3.42–3.74
Vc (L) = exp(hpop,2) 8.1
hpop, 2 2.09 24.4 0.509 1.09–3.09
Q1 (L/h) = exp(hpop,3) 28.2
hpop, 3 3.34 10.4 0.347 2.66–4.02
V2 (L) = exp(hpop,4) 35.9
hpop, 4 3.58 6.09 0.218 3.15–4.01
Q2 (L/h) = exp(hpop,5) 5.7
hpop, 5 1.74 11.5 0.200 1.35–2.13
V3 (L) = exp(hpop,6) 115.6
hpop,6 4.75 4.90 0.233 4.29–5.21
VSS (L) = Vc ? V2 ? V3 160
Terminal half-life (h)d 16
BMI covariate on CL 1.36 18.5 0.252 0.866–1.85
BMI covariate on Q2 2.42 19.8 0.479 1.4–3.36
Inter-individual variability
CL 0.0991 23.1 0.0229 31.5
Q2 0.226 41.4 0.0936 47.5
Residual variability
Sigma 0.144 16.2 0.0234 37.9
Shrinkage: 5.56% on CL, 26.5% on Q2, and 8.06% on Sigma
Condition number 90.63
BMI Body mass index, CI confidence interval, CL clearance, CV coefficient of variation, Q1 and Q2 inter-
compartmental clearance, RSE relative standard error, Vc volume of distribution of the central compart-
ment, V2 and V3 volume of distribution of the peripheral compartments
a %RSE = 100% 9 STD ERR/EST, STD ERR standard error, EST estimate
b 95% CI = EST ± 1.96 9 STD ERR, STD ERR standard error
c %CV = 100% 9 SQRT(EST) for ETA(p) and EPS(q), SQRT square root, ETA(p) refers to variance of
Inter-individual variability, EPS(p) refers to Sigma (variance of residual error)
d Terminal half-life was calculated based on typical value of CL, Vc, V2, V3, Q1, and Q2
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used to produce the visual predictive check analysis and
plotting.
3 Results
3.1 Demographics and Baseline Characteristics
A total of 57 subjects received at least one dose of
dilmapimod, and 20 subjects were randomised to receive
placebo in the four cohorts. A summary of the demographic
variables and the baseline characteristics of the population
is presented in Christie et al. [10].
Briefly, the median age across all subjects was 39 years.
Themedian body weight and height were 86 kg and 175 cm,
respectively, with a median body mass index (BMI) of
27 kg/m2. The median values for ISS total injury score and
Glasgow Coma Score were 25 and 15, respectively, indi-
cating severe/critical trauma and mild brain injury,
respectively. The median time since trauma was about 22 h,
with a range of 9–28 h. It was noted that only a small number
of subjects were dosed in the early time post injury (four
subjects were dosed within the first 12 h following injury, 41
were dosed between 12 and 24 h following injury, and 28
subjects were dosed between 24 and 36 h post injury).
Overall, there was no observable difference in demo-
graphics and baseline characteristics among the different
treatment groups.
3.2 Population PK Results
The dilmapimod plasma concentration following intra-
venous infusion was adequately described by a three-
compartment model with first-order elimination (left panel,
Fig. 1). Table 2 shows the parameter estimates of the final
PK model.
The fixed-effect parameters were estimated with good
precision, with %RSE ranging between 2.25 and 24.4%.
Fig. 2 Basic goodness-of-fit plots for the final dilmapimod pharma-
cokinetic model. Observed dilmapimod concentrations (ng/mL) are
plotted vs. population and individual predictions (top). Conditional
weighted residuals are plotted against time and population predictions
(bottom). The empty circles represent the data points. The solid black
line in each plot is the line of identity
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The inter-individual variability for CL and Q2 were mod-
erate (31.5% and 47.5%, respectively). The effect of BMI
on CL and Q2 was modelled using a power model with the
covariate centred to the population mean of 27.4 kg/m2. An
increase in BMI of 1 kg/m2 resulted in a 1.79 L/h and
0.52 L/h increase in CL and Q2, respectively.
The proportional error model was adequate, and the
residual variability was about 38%. The population clear-
ance (CL) parameter value was 35.87 L/h, and the steady-
state volume of distribution (Vss) (sum of Vc, V2, and V3)
was 160 L. A two-compartment model was tested and
found not as good as a three-compartment model.
Standard model diagnostics and visual predictive check
were conducted to assess the validity of the model. Fig-
ure 2 shows the goodness of fit for population predicted
versus observed, individual predicted versus observed,
conditional weighted residual versus time, and conditional
weighted residuals versus population predicted concentra-
tions. Figure 3 shows the visual predictive check for the
final model.
Dilmapimod plasma concentrations–time courses for
each subject included in the analysis dataset were predicted
from the final model, using their individual parameter and
BMI values and individual dosing history. The predicted
individual plasma concentrations at the sampling time
where the PD data were collected were merged with the PD
dataset for the following PK/PD analysis. The daily
exposure AUC(0–24) and maximum concentration (Cmax),
which were estimated from the final PK model for each
individual in the dataset, are summarised by cohort and
day. The results are presented in Christie et al. [10].
3.3 CRP PK/PD Modelling Results
A base model development was initiated to describe the
time course of the systemic CRP levels without a drug
effect included in the model, assuming that the CRP levels
will quickly increase after injury, reach a peak and then
gradually decrease (Eqs. 3, 4). The base model parameter
estimates of fixed and random effects are presented in
Fig. 3 Visual predicted check from 1000 simulated data sets for the
final dilmapimod pharmacokinetic model. The 95% confidence
interval (CI) of the median of the simulated data is represented by
the dark grey area. The 95% CI of the 2.5th and 97.5th percentiles of
the simulated data are represented by the light grey areas. The
observed data are represented by the black open circles. The median
of the observed data is represented by the solid line. The 2.5th and
97.5th percentiles of the observed data are represented by the dashed
lines
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Table 3. All fixed-effect parameters were estimated with
good precision. Inter-individual variability was estimated
for all parameters with moderate to relatively high preci-
sion (from 48% to 61%).
Figure 4 shows the model predicted CRP profiles for
four representative subjects, one in each treatment group,
along with the observed data, and indicates that the model
describes the shape of the systemic CRP time course
Table 3 Parameter estimates of
fixed and random effects from
the base (no drug effect) CRP
pharmacokinetic/
pharmacodynamic model
Parameter (unit) Typical value %RSEa Standard error 95% CIb or %CVc
Kdecline (h
-1) = exp(hpop,1) 0.008
hpop,1 -4.77 -3.92 0.187 -5.14 to -4.40
Kin0 (h
-1) = exp(hpop,2) 7.171
hpop,2 1.97 3.17 0.0625 1.85 to 2.09
Kout (h
-1) = exp(hpop,3) 0.026
hpop,3 -3.64 -4.01 0.146 -3.93 to -3.35
Inter-individual variability
Kdecline 0.377 40.8 0.154 61.4
Kin0 0.230 19.3 0.0444 48.0
Kout 0.373 29.5 0.110 61.1
Residual variability
Sigma 0.216 3.44 7.44e-03 46.5
Shrinkage: 39.0% on Kdecline, 5.80% on Kin0, 27.2% on Kout, and 9.93% on Sigma
Condition number 9.91
CI Confidence interval, CRP C-reactive protein, CV coefficient of variation, Kdecline gradual decline in
production rate over time, Kin0 CRP production rate immediately following injury, Kout first-order elimi-
nation rate constant of CRP, RSE relative standard error
a %RSE = 100% 9 STD ERR/EST, STD ERR standard error, EST estimate
b 95% CI = EST ± 1.96 9 STD ERR, STD ERR standard error
c %CV = 100% 9 SQRT(EST) for ETA(p) and EPS(q), SQRT square root, ETA(p) refers to variance of
Inter-individual variability, EPS(p) refers to Sigma (variance of residual error)
Fig. 4 Individual C-reactive protein (CRP) profiles from four
representative subjects, two in each treatment group. The observed
CRP concentrations are represented by the black open circles. The
population and individual predictions are represented by the dashed
and solid lines, respectively
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reasonably well. The goodness-of-fit plots (Fig. 5) did not
show any obvious bias. The visual predictive check plots
(Fig. 6) indicate reasonable fit of the model to the data,
albeit the variability of the prediction was high.
An initial graphical analysis was conducted to explore
the need for a dilmapimod drug effect term in the model.
Examination of inter-subject variability (ETAs) versus
treatment regimen (Fig. 7a) and versus dilmapimod expo-
sure (AUC) (Fig. 7b) revealed potential drug effects on
Kdecline (describing the gradual decline in production rate
overtime), Kin0, and on Kout (first-order elimination rate
constant of CRP).
3.3.1 Drug-Effect Model
Based on the current understanding of the p38 pathway, the
potential association between systemic exposure of
dilmapimod and CRP biomarker was investigated. Thus,
the effect of dilmapimod on CRP was first assessed using
inhibitory models, assuming that inhibition of the p38
pathway by dilmapimod would result in an inhibition of the
production rate of CRP (Table 1). However, this modelling
approach did not result in an acceptable drug-effect model
(data not shown). Furthermore, based on the graphical
analysis presented in Fig. 7, additional stimulatory mech-
anistic drug-effect models on Kdecline and Kout were
explored (Table 1). None of these models resulted in an
acceptable drug-effect model for the dataset under evalu-
ation (data not shown).
4 Discussion
In this work, we present a population PK and PK/PD
approach to assist the understanding of PK and PD profiles
following intravenous infusion of dilmapimod.
The plasma concentration data of dilmapimod obtained
in this study were best described by a three-compartment
Fig. 5 Basic goodness-of-fit plots for the base C-reactive protein
(CRP) model. Observed CRP concentrations (mg/L) are plotted vs.
population and individual predictions (top). Conditional weighted
residuals are plotted against time and population predictions (bottom).
The empty circles represent the data points. The solid line in each plot
is the line of identity
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model, with inter-individual variability added on clearance
and inter-compartment clearance Q2. Data did not support
adding inter-individual variability on other PK parameters.
Among all the demographic and baseline covariates, BMI
was found to be a statistically significant covariate on CL
and Q2. Based on the final population PK model, the
clearance for dilmapimod for the typical patient (mean
BMI of 27.4 kg/m2) in the current study was 36 L/h. The
clearance was about 21% lower and 23% higher for
patients with BMI of 23 kg/m2 [mean - standard devia-
tion (SD)] and 32 kg/m2 (mean ? SD) compared with the
typical patients, respectively. The BMI effect on dilmapi-
mod clearance is not completely unexpected as a slight
correlation of BMI with oral clearance in healthy individ-
uals and chronic obstructive pulmonary disease (COPD)
patients has been previously observed (data not shown).
This correlation may be explained by the fact that
dilmapimod is eliminated almost exclusively by metabo-
lism (hydroxylation and glucuronidation as the primary
routes of metabolism), and obesity was shown to increase
both phase I and phase II metabolism of various medica-
tions [16–19]. However, the changes in clearance and
therefore total systemic exposure (dose/CL) were not
considered clinically significant; therefore, dose adjust-
ments were not considered necessary at this stage.
Exploratory analyses conducted to assess the impact of
dilmapimod on CRP showed a trend of lower levels of CRP
present at later time points (e.g. 72 h post dose) at all
dilmapimod dose levels, relative to placebo [10]. The
decrease in CRP levels was most apparent with the con-
tinuous infusion of 10 mg/24 h [10].
The potential association between the systemic exposure
of dilmapimod and CRP levels was explored using mech-
anistic modelling. An initial base model described the
systemic CRP levels without drug effect based on the
assumptions that after injury, CRP levels quickly increase,
reach a peak and then gradually decrease. Although the
time of injury was known for patients with trauma, there
was no actual measurement of CRP until the subject was
randomised in the study. Therefore, the baseline CRP level
was set at the normal level for CRP. Even though the base
model overpredicts the CRP variability, this approach is
considered appropriate as these subjects were generally
healthy before the injury. The overprediction of CRP
variability may be due to the high variability in the timing
of treatment initiation relative to the time of trauma
(ranging between 4 and 36 h), or due to the severity and
type of injury.
Exploration of individual parameters Kin0, Kdecline, and
Kout by treatment group, and systemic exposure of
dilmapimod (AUC) indicated a potential effect of
dilmapimod on reduction of Kin0 or stimulation of Kdecline
and Kout. However, when the effect of dilmapimod on the
CRP level was investigated, the indirect response mod-
elling approaches did not result in an acceptable drug-ef-
fect model. This could be due to the high variability
observed in CRP levels, or the relatively narrow dose and
systemic exposure ranges. Similar a PK/PD modelling
Fig. 6 Visual predicted check
from 1000 simulated data sets
for the base C-reactive protein
(CRP) model. The 95%
confidence interval (CI) of the
median of the simulated data is
represented by the dark grey
area. The 95% CI of the 2.5th
and 97.5th percentiles of the
simulated data are represented
by the light grey areas. The
observed data are represented
by the black open circles. The
median of the observed data is
represented by the solid line.
The 2.5th and 97.5th percentiles
of the observed data are
represented by the dashed lines
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approach was also conducted on IL-6 data in this study
[20]. However, the overall effect of dilmapimod on IL-6
levels was not revealed via such a modelling frame, in spite
of some observed effect of dilmapimod at some time points
[10].
Dilmapimod intravenous infusion up to 10 mg was gen-
erally well tolerated in patients with severe trauma at risk of
ARDS. Evidence of hepatotoxicity has been associated with
some p38 MAPK inhibitors [21, 22], which led to cautious
selection of dilmapimod’s top dose in this study.
Another important factor for the ability to develop a
mechanistic drug-effect model for dilmapimod may be the
time of treatment start. Transcription of CRP is regulated
by pro-inflammatory cytokines, including IL-6 [23, 24],
and therefore, a reduction in IL-6 should precede a
decrease in CRP. Indeed, evaluation of serum IL-6 and
CRP fluctuation in children with severe head injury showed
serum IL-6 values peaked 4 h post injury, followed by a
decrease over time, while the CRP levels reached peak
levels between 24 and 48 h, decreasing thereafter [22]. In
this study, only four subjects were dosed within 12 h post
injury, 41 subjects were dosed between 12 and 24 h post
injury, and 28 subjects were dosed after 24 h. Given the
role of IL-6 in transcriptional regulation of CRP and the
long half-life of CRP (measured in days), it is possible that
administration of the p38 MAPK inhibitor dilmapimod
shortly after injury would result in a more robust preven-
tion of injury-induced elevation in CRP levels [24].
Exploratory analyses conducted to assess the impact of
dilmapimod on IL-6 showed a trend of lower levels of IL-6
present 24 h post dose at all dilmapimod dose levels, rel-
ative to placebo [10]. The continuous infusion of 10 mg/
24 h was the only dose level that yielded ratios of IL-6
relative to placebo below 1 up to 72 h post dose [10].
Consistent with the role of IL-6 in the transcriptional reg-
ulation of CRP, the decrease in IL-6 following dilmapimod
administration preceded the decrease in CRP [10]. There-
fore, an alternative modelling strategy could be a modified
indirect response model that describes the stimulatory
effect of IL-6 on the production rate of CRP, with
dilmapimod having indirect inhibitory activity on IL-6
production.
Fig. 7 Box plot of estimated random effects on Kdecline (ETA1), Kin0
(ETA2), and Kout (ETA3) by treatment groups for the base C-reactive
protein (CRP) model (a). Linear regression plots of the estimated
random effects vs. AUC (ngh/mL) (b). The empty circles represent
the data points. The solid lines represent linear regression lines. AUC
area under the concentration–time curve, Kdecline decline in CRP
production rate over time, Kin0 CRP production rate immediately
following injury, Kout first-order elimination rate constant of CRP
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5 Conclusions
Dilmapimod plasma concentration–time profiles in severe
trauma subjects at risk for ARDS were described by a
three-compartment model. Following intravenous dosing,
dilmapimod was quickly distributed to peripheral com-
partments and then slowly eliminated in a multi-exponen-
tial manner. The plasma concentration of dilmapimod
increased approximately proportionally to the increase in
dose. BMI was found to be a significant covariate for CL
and Q2.
The CRP profile post injury was adequately described
by an indirect response model, with a sharp increase in the
CRP levels following injury, then them slowly diminishing.
Although data exploration indicated potential drug effects
of dilmapimod inhibiting the production of CRP levels, the
current small dataset did not show a statistically significant
improvement in the PK/PD modelling.
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